Abstract
Objective Lung cancer is a primary cause of cancer death. This study assessed the action of
dexmedetomidine (DEX) on oxidative stress (OS) and microRNA 10a (miR-10a) in patients
with lung cancer.
Methods Patients were given 1 µg/kg DEX before anesthesia and control patients were given
saline. The duration of intraoperative one-lung ventilation (OLV) and fluid intake
were determined, and mean arterial pressure, heart rate and bispectral index were
observed at the time of before anesthesia (T0), immediately after endotracheal intubation
(T1), 1 hour after OLV (T2), and 10 minutes before the end of surgery (T3). The expressions
and correlations of miR-10a, inflammation and OS levels in the serum were analyzed.
The effects of DEX intervention and miR-10a level on pulmonary complications were
analyzed.
Results Patients with DEX intervention had lower levels of inflammation and OS during perioperative
period than the controls. DEX intervention reduced miR-10a levels in patients during
perioperative period. miR-10a in serum of patients with DEX intervention after surgery
was positively-correlated with the concentrations of malondialdehyde, and inflammatory
factors, while negatively-correlated with superoxide dismutase. The total incidence
of postoperative pulmonary complications after DEX intervention was lowered. Patients
with high miR-10a expression had a higher cumulative incidence of pulmonary complications
than those with low miR-10a expression.
Conclusion DEX can reduce postoperative OS and plasma miR-10a level in patients with lung cancer,
and high expression of miR-10a predicts a high incidence of postoperative pulmonary
complications.
Keywords
dexmedetomidine - lung cancer - miR-10a - inflammatory cytokines - oxidative stress
- pulmonary complications - Pearson coefficients
